Standout Papers
Immediate Impact
2 by Nobel laureates 63 standout
Citing Papers
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
2023 Standout
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
2023 Standout
Works of Mary Catlin being referenced
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Mary Catlin | 182 | 543 | 499 | 9 | 962 | |
| Carol Pertowski | 176 | 221 | 467 | 11 | 1.1k | |
| Mats Erntell | 213 | 171 | 221 | 21 | 964 | |
| Audrey Smith Rogers | 361 | 217 | 197 | 29 | 1.0k | |
| Harrison F. Wood | 39 | 367 | 246 | 31 | 1.0k | |
| Cheryl N. McMahill‐Walraven | 82 | 352 | 179 | 37 | 1.0k | |
| Keith I. Marton | 300 | 186 | 178 | 31 | 1.2k | |
| Edmond S. W. Ng | 198 | 129 | 265 | 21 | 1.0k | |
| Louise E. Vaz | 109 | 338 | 309 | 32 | 755 | |
| Michael Waller | 215 | 255 | 417 | 8 | 1.0k | |
| Lawrence F. Nazarian | 109 | 95 | 276 | 27 | 1.0k |
All Works
Loading papers...